WO2013166166A1 - Use of high dose laquinimod for treating multiple sclerosis - Google Patents
Use of high dose laquinimod for treating multiple sclerosis Download PDFInfo
- Publication number
- WO2013166166A1 WO2013166166A1 PCT/US2013/039090 US2013039090W WO2013166166A1 WO 2013166166 A1 WO2013166166 A1 WO 2013166166A1 US 2013039090 W US2013039090 W US 2013039090W WO 2013166166 A1 WO2013166166 A1 WO 2013166166A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laquinimod
- patient
- administration
- human patient
- multiple sclerosis
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title claims abstract description 260
- 229960004577 laquinimod Drugs 0.000 title claims abstract description 255
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 claims abstract description 105
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 230000001965 increasing effect Effects 0.000 claims abstract description 43
- 206010061818 Disease progression Diseases 0.000 claims abstract description 39
- 230000005750 disease progression Effects 0.000 claims abstract description 39
- 208000024806 Brain atrophy Diseases 0.000 claims abstract description 34
- 239000002552 dosage form Substances 0.000 claims abstract description 25
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims abstract description 21
- 239000003937 drug carrier Substances 0.000 claims abstract description 15
- 230000004112 neuroprotection Effects 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 107
- 230000003902 lesion Effects 0.000 claims description 59
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 230000008859 change Effects 0.000 claims description 25
- 230000036541 health Effects 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 18
- 230000003247 decreasing effect Effects 0.000 claims description 17
- 210000003169 central nervous system Anatomy 0.000 claims description 16
- 230000009266 disease activity Effects 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 14
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- 229960005027 natalizumab Drugs 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 208000028698 Cognitive impairment Diseases 0.000 claims description 10
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 10
- 229960000556 fingolimod Drugs 0.000 claims description 10
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 10
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 10
- 238000009825 accumulation Methods 0.000 claims description 9
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 8
- 230000006866 deterioration Effects 0.000 claims description 8
- 229960003776 glatiramer acetate Drugs 0.000 claims description 8
- 229960001156 mitoxantrone Drugs 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000001537 neural effect Effects 0.000 claims description 5
- 230000009223 neuronal apoptosis Effects 0.000 claims description 5
- 230000006764 neuronal dysfunction Effects 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229960004461 interferon beta-1a Drugs 0.000 claims description 4
- 229960003161 interferon beta-1b Drugs 0.000 claims description 4
- 238000009097 single-agent therapy Methods 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 230000003340 mental effect Effects 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 44
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 229940068196 placebo Drugs 0.000 description 35
- 239000000902 placebo Substances 0.000 description 35
- 239000003814 drug Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 26
- 238000012216 screening Methods 0.000 description 16
- 102000014150 Interferons Human genes 0.000 description 13
- 108010050904 Interferons Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 206010016256 fatigue Diseases 0.000 description 13
- 230000000926 neurological effect Effects 0.000 description 13
- 229940079322 interferon Drugs 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 210000001428 peripheral nervous system Anatomy 0.000 description 10
- 230000005415 magnetization Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 229940003504 avonex Drugs 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 5
- 230000003862 health status Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940079023 tysabri Drugs 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010051290 Central nervous system lesion Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 238000008789 Direct Bilirubin Methods 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000007844 axonal damage Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940126602 investigational medicinal product Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940038850 rebif Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MISZALMBODQYFT-URVXVIKDSA-N 125-69-9 Chemical compound Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MISZALMBODQYFT-URVXVIKDSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 238000012276 Endovascular treatment Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001379910 Ephemera danica Species 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940121538 choriogonadotropin beta Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002597 diffusion-weighted imaging Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000011234 economic evaluation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003838 injectable contraceptive agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000010234 longitudinal analysis Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000013442 quality metrics Methods 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- -1 salt ion Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- JWHPPWBIIQMBQC-UHFFFAOYSA-M sodium;5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate Chemical compound [Na+].[O-]C=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 JWHPPWBIIQMBQC-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000036409 touch and pain Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- MS Multiple Sclerosis
- MS is mediated by some kind of autoimmune process possibly triggered by infection and superimposed upon a genetic predisposition. It is a chronic inflammatory condition that damages the myelin of the Central Nervous System (CNS) .
- CNS Central Nervous System
- the pathogenesis of MS is characterized by the infiltration of autoreactive T-cells from the circulation directed against myelin antigens into the CNS. (Bjartmar, 2002)
- axonal loss occurs early in the course of the disease and can be extensive over time, leading to the subsequent development of progressive, permanent, neurologic impairment and, frequently, severe disability.
- Symptoms associated with the disease include fatigue, spasticity, ataxia, weakness, bladder and bowel disturbances, sexual dysfunction, pain, tremor, paroxysmal manifestations, visual impairment, psychological problems and cognitive dysfunction.
- EMEA Guideline 2006
- the interferons and glatiramer acetate are delivered by frequent injections, varying from once-per-day for glatiramer acetate to once-per-week (but intra-muscular) for Avonex®.
- Natalizumab and mitoxantrone are given by IV infusion at monthly intervals. Most of them are believed to act as immunomodulators .
- Mitoxantrone and natalizumab are believed to act as immunosuppressants.
- the mechanisms of action of each have been only partly elucidated. Immunosuppressants or cytotoxic agents are used in some subjects after failure of conventional therapies. However, the relationship between changes of the immune response induced by these agents and the clinical efficacy in MS is far from settled. (EMEA Guideline, 2006)
- symptomatic treatment refers to all therapies applied to improve the symptoms caused by the disease (EMEA Guideline, 2006) and treatment of acute relapses with corticosteroids. While steroids do not affect the course of MS over time, they can reduce the duration and severity of attacks in some subjects.
- Laquinimod Laquinimod sodium is a novel synthetic compound with high oral bioavailability, which has been suggested as an oral formulation for the treatment of MS. (Polman, 2005; Sandberg-Wollheim, 2005)
- the relevant efficacy parameter for clinical trials is the accumulation of disability and relapse rate (for RRMS) .
- RRMS disability and relapse rate
- the subject invention provides a method of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, the method comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of about 1.2 mg laquinimod so as to thereby treat the human patient.
- the subject invention also provides a method of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient, the method comprising orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of about 1.2 mg laquinimod so as to thereby treat the human patient by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient.
- the subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human subject by providing neuroprotection to the human subject, and a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient.
- the subject invention provides a method of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, the method comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of about 1.2 mg laquinimod so as to thereby treat the human patient.
- the administration laquinimod is effective to alleviate a symptom of or a condition associated with multiple sclerosis.
- the administration of laquinimod is effective to increase the time to confirmed disease progression, increase the time to confirmed relapse, reduce brain atrophy, reduce relapse rate, reduce rate of confirmed relapses requiring hospitalization and/or IV steroids, reduce the accumulation of disability, reduce or inhibit progression of the level of fatigue, improve or inhibit deterioration of the functional status, improve or inhibit deterioration of the general health, reduce MRI-monitored disease activity or reduce cognitive impairment in the human patient.
- the administration of laquinimod is effective to increase the time to confirmed disease progression in the human patient.
- the administration of laquinimod is effective to reduce brain atrophy in the human patient.
- brain atrophy is reduced by 15-40%.
- brain atrophy is reduced by at least 20%.
- brain atrophy is reduced by at least 30%.
- brain atrophy is reduced by at least 40%.
- brain atrophy is reduced by at least 50%.
- the administration of laquinimod is effective to reduce relapse rate in the human patient. In another embodiment, the relapse rate is reduced by at least 20%. In another embodiment, the relapse rate is reduced by at least 30%.
- the relapse rate is reduced by at least 50%. In another embodiment, the relapse rate is reduced by at least 60%. In yet another embodiment, the relapse rate is reduced by at least 70%.
- the administration of laquinimod is effective to reduce the accumulation of disability in the human patient.
- the accumulation of disability is assessed by the timed 25-foot walk (T25FW) .
- the accumulation of disability is assessed by the progression of the subject's MS Functional Composite (MSFC) score.
- patient's MSFC score improves within 3 months of first laquinimod treatment.
- patient's MSFC score improves within 6 months of first laquinimod treatment.
- patient's MSFC score improves within 12 months of first laquinimod treatment.
- patient's MSFC score improves within 18 months of first laquinimod treatment.
- patient's MSFC score improves within 24 months of first laquinimod treatment.
- the administration of laquinimod reduces patient's risk for a confirmed disease progression by at least 30%, compared to a patient not receiving the laquinimod treatment. In another embodiment, the administration of laquinimod reduces patient's risk for a confirmed disease progression by at least 35%, compared to a patient not receiving the laquinimod treatment. In another embodiment, the administration of laquinimod reduces patient's risk for a confirmed disease progression by at least 40%, compared to a patient not receiving the laquinimod treatment. In an embodiment, the risk reduction occurred within 3 months of first laquinimod treatment. In another embodiment, the risk reduction occurred within 6 months of first laquinimod treatment.
- the risk reduction occurred within 12 months of first laquinimod treatment. In another embodiment, the risk reduction occurred within 18 months of first laquinimod treatment. In another embodiment, the risk reduction occurred within 24 months of first laquinimod treatment.
- the administration of laquinimod is effective to reduce or inhibit progression of the level of fatigue in the human patient. In an embodiment, the level of fatigue is assessed by the patient's Modified Fatigue Impact Scale (MFIS) score. In another embodiment, the administration of laquinimod decreased the human patient's MFIS score, compared to a patient not receiving the laquinimod treatment.
- MFIS Modified Fatigue Impact Scale
- the administration of laquinimod decreased the human patient's MFIS score, compared to the patient at the start of the laquinimod treatment. In yet another embodiment, the MFIS score decreased within 24 months of the start of laquinimod treatment. In one embodiment, the administration of laquinimod is effective to improve or inhibit deterioration of the functional status in the human patient. In another embodiment, the functional status of the patient is measured by the patient' s Short-Form General Health survey (SF-36) Subject-Reported Questionnaire score. In another embodiment, the administration of laquinimod decreased the human patient's SF-36 score, compared to a patient not receiving the laquinimod treatment.
- SF-36 Short-Form General Health survey
- the administration of laquinimod decreased the human patient's SF-36 score, compared to the patient at the start of the laquinimod treatment.
- the patient's SF-36 mental component summary score (MSC) is decreased.
- the patient's SF-36 physical component summary score (PSC) is decreased.
- the SF-36 score is decreased within 24 months of the start of laquinimod treatment.
- the administration of laquinimod is effective to improve or inhibit deterioration of the general health in the human patient.
- the general health of the patient is assessed by the patient's EQ-5D Standardized Questionnaire score.
- the administration of laquinimod increased the human patient's EQ-5D score, compared to a patient not receiving the laquinimod treatment. In another embodiment, the administration of laquinimod increased the human patient's EQ-5D score, compared to the patient at the start of the laquinimod treatment. In another embodiment, the EQ-5D score increased within 24 months of the start of laquinimod treatment.
- the administration of laquinimod is effective to reduce MRI-monitored disease activity in the human patient.
- the MRI-monitored disease activity is assessed by the number of GdE-Tl lesions, the number of new T2 lesions, the number of new Tl hypointense lesions (black holes) , change in T2 lesions volume, change in GdE-Tl lesions volume or change in Tl hypointense lesions volume (black holes) .
- the MRI-monitored disease activity is the cumulative number of enhancing lesions on Tx-weighted images, the cumulative number of new hypointense lesions on Tuscans, and the cumulative number of new T 2 lesions.
- the MRI-monitored disease activity is the mean cumulative number of Gd-Enhancing lesions, Gd-enhanced lesion counts, change in T 2 visible lesion or change in brain volume.
- the administration of laquinimod is effective to reduce cognitive impairment in the human patient.
- the cognitive impairment is assessed by the Symbol Digit Modalities Test (SDMT) score.
- SDMT Symbol Digit Modalities Test
- the patient had disease duration of at least 6 months prior to starting laquinimod treatment.
- the laquinimod is administered as monotherapy for multiple sclerosis. In another embodiment, the laquinimod is administered as adjunct therapy with another multiple sclerosis treatment. In another embodiment, the other relapsing-remitting multiple sclerosis treatment is administration of interferon beta 1-a, interferon beta 1-b, glatiramer acetate, mitoxantrone, natalizumab, dialkyl fumarate or fingolimod. In yet another embodiment, the human patient is afflicted with relapsing- remitting multiple sclerosis.
- the subject invention also provides a method for treating a human subject by providing neuroprotection to the human subject comprising orally administering to the human subject a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof so as to thereby treat the human subject by providing neuroprotection to the human subject.
- the administration of laquinimod reduces neuronal dysfunction, reduces neuronal injury, reduces neuronal degeneration, and/or reduces neuronal apoptosis. In another embodiment, the administration of laquinimod reduces neuronal dysfunction in the Central Nervous System, reduces neuronal injury in the Central Nervous System, reduces neuronal degeneration in the Central Nervous System, an/or reduces neuronal apoptosis in the Central Nervous System.
- the administration of laquinimod reduces neuronal dysfunction in the peripheral nervous system consists, reduces neuronal injury in the peripheral nervous system (PNS), reduces neuronal degeneration in the peripheral nervous system (PNS) , an/or reduces neuronal apoptosis in the peripheral nervous system (PNS) .
- the method of any of the above comprises orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of substantially 1.2 mg laquinimod. In another embodiment, the method comprises orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of 1.2 mg laquinimod. In another embodiment, the laquinimod is administered in the form of laquinimod sodium.
- the administration is for a period of greater than 24 weeks. In another embodiment of any of the methods described herein, the administration is for a period of greater than 36 weeks. In another embodiment of any of the methods described herein, the administration is for a period of greater than 48 weeks.
- the subject invention also provides a method of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient, the method comprising orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of about 1.2 mg laquinimod so as to thereby treat the human patient by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient.
- the administration laquinimod is effective to increase the time to confirmed disease progression in the human patient.
- the administration of laquinimod is effective to increase the time to confirmed relapse in the human patient.
- the administration of laquinimod is effective to reduce brain atrophy in the human patient .
- the method comprises orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of 1.2 mg laquinimod.
- the laquinimod is administered in the form of laquinimod sodium.
- the administration is for a period of greater than 24 weeks. In another embodiment of any of the methods described herein, the administration is for a period of greater than 36 weeks. In another embodiment of any of the methods described herein, the administration is for a period of greater than 48 weeks.
- the laquinimod or pharmaceutically acceptable salt thereof is administered in the form of a tablet. In another embodiment, the laquinimod or pharmaceutically acceptable salt thereof is administered in the form of a capsule.
- the subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
- the subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human subject by providing neuroprotection to the human subject.
- the subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient.
- the pharmaceutical oral unit dosage form contains substantially 1.2 mg laquinimod. In another embodiment, the pharmaceutical oral unit dosage form contains 1.2 mg laquinimod .
- the pharmaceutical oral unit dosage form is in the form of a tablet. In another embodiment, the pharmaceutical oral unit dosage form is in the form of a capsule.
- the subject invention also provides a method of reducing the likelihood that a relapsing-remitting multiple sclerosis human patient would experience a confirmed relapse within a predetermined time period, the method comprising orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of about 1.2 mg laquinimod so as to thereby reduce the likelihood that the relapsing- remitting multiple sclerosis human patient would experience a confirmed relapse within the predetermined period.
- the predetermined time period is 12 months. In another embodiment, the predetermined time period is 24 months.
- the relapse rate or the likelihood (risk) of relapse is reduced by at least 20%, compared to a patient not receiving the laquinimod treatment. In another embodiment, the relapse rate or the likelihood (risk) of relapse is reduced by at least 25%, compared to a patient not receiving the laquinimod treatment. In another embodiment, the relapse rate or the likelihood (risk) of relapse is reduced by at least 30%, compared to a patient not receiving the laquinimod treatment. In yet another embodiment, the relapse rate or the likelihood (risk) of relapse is reduced by at least 70%, compared to a patient not receiving the laquinimod treatment.
- the subject invention further provides a method of decreasing the severity or duration of a relapse in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of about 1.2 mg laquinimod so as to thereby decrease the severity or duration of the relapse in the relapsing-remitting multiple sclerosis human patient.
- the administration of the laquinimod increased the odds of the patient to be relapse-free.
- the patient receiving laquinimod had approximately 55% better odds to be relapse-free, compared to a patient not receiving the laquinimod treatment.
- the patient' s annualized relapse rate for the first year of treatment is reduced, compared to a patient not receiving the laquinimod treatment.
- the reduction is by at least 20%.
- the risk of the patient experiencing a relapse severe enough to require hospitalization is reduced, compared to a patient not receiving the laquinimod treatment.
- the risk is reduced by at least 20% or at least 30%.
- the risk of the patient experiencing a relapse severe enough to require IV-steroids treatment is reduced, compared to a patient not receiving the laquinimod treatment.
- the risk is reduced by at least 20% or at least 30%, compared to a patient not receiving the laquinimod treatment.
- oral administration of laquinimod or a pharmaceutically acceptable salt thereof to the relapse-remitting multiple sclerosis human patient at a daily dose of about 1.2 mg laquinimod improves the odds of the patient being free of disease or disease activity.
- the patient's odds of being disease free is increased by at least 50% or at least 55%, compared to a patient not receiving the laquinimod treatment.
- the patient's odds of being free of disease activity is increased by at least 40% or at least 45%, compared to a patient not receiving the laquinimod treatment .
- the method comprises orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of substantially 1.2 mg laquinimod. In another embodiment, the method comprises orally administering to the patient laquinimod or a pharmaceutically acceptable salt thereof at a daily dose of 1.2 mg laquinimod. In another embodiment, the laquinimod is administered in the form of laquinimod sodium.
- the laquinimod or pharmaceutically acceptable salt thereof is administered in the form of a tablet. In another embodiment, the laquinimod or pharmaceutically acceptable salt thereof is administered in the form of a capsule.
- the efficacy of laquinimod is measured as compared to a patient not receiving the laquinimod treatment. In another embodiment, the efficacy of laquinimod is measured as compared to the patient at the start of the laquinimod treatment.
- the subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in reducing the likelihood that the relapsing-remitting multiple sclerosis human patient would experience a confirmed relapse within a predetermined time period, for reducing the severity or duration of a relapse in the relapsing-remitting multiple sclerosis human patient, for improving quality of life and general health of a relapsing-remitting multiple sclerosis human patient, or for improving the odds of a relapsing-remitting multiple sclerosis human patient for being free of disease or disease activity.
- the pharmaceutical oral unit dosage form contains substantially 1.2 mg laquinimod.
- the pharmaceutical oral unit dosage form contains 1.2 mg laquinimod.
- the pharmaceutical oral unit dosage form is in the form of a tablet. In another embodiment, the pharmaceutical oral unit dosage form is in the form of a capsule.
- each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiment .
- a pharmaceutically acceptable salt of laquinimod as used in this application includes lithium, sodium, potassium, magnesium, calcium, manganese, copper, zinc, aluminum and iron. Salt formulations of laquinimod and the process for preparing the same are described, e.g., in U.S. Patent Application Publication No. 2005/0192315 and PCT International Application Publication No. WO 2005/074899, which are hereby incorporated by reference into this application .
- a dosage unit may comprise a single compound or mixtures of compounds thereof.
- a dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, and granules.
- Laquinimod can be administered in admixture with suitable pharmaceutical diluents, extenders, excipients, or carriers (collectively referred to herein as a pharmaceutically acceptable carrier) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
- the unit will be in a form suitable for oral administration.
- Laquinimod can be administered alone but is generally mixed with a pharmaceutically acceptable carrier, and co-administered in the form of a tablet or capsule, liposome, or as an agglomerated powder.
- suitable solid carriers include lactose, sucrose, gelatin and agar.
- Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents flow-inducing agents, and melting agents.
- Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
- the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like.
- Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
- “Laquinimod” means laquinimod acid or a pharmaceutically acceptable salt thereof.
- a “salt” is salt of the instant compounds which have been modified by making acid or base salts of the compounds.
- pharmaceutically acceptable salt in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention.
- a “dose of 1.2 mg laquinimod” means the amount of laquinimod acid in a preparation is 1.2 mg, regardless of the form of the preparation. Thus, when in the form of a salt, e.g. a laquinimod sodium salt, the weight of the salt form necessary to provide a dose of 1.2 mg laquinimod would be greater than 1.2 mg due to the presence of the additional salt ion.
- administering to the subject means the giving of, dispensing of, or application of medicines, drugs, or remedies to a subject to relieve, cure, or reduce the symptoms associated with a disease, disorder or condition.
- "effective" as in an amount effective to achieve an end means the quantity of a component that is sufficient to yield an indicated therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this disclosure. For example, an amount effective to treat multiple sclerosis.
- the specific effective amount will vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any) , and the specific formulations employed and the structure of the compounds or its derivatives.
- to “treat” or “treating” encompasses, e.g., inducing inhibition, regression, or stasis of, or ameliorating or alleviating a symptom of, a disease and/or condition.
- inhibittion of disease progression or complication in a subject means preventing or reducing the disease progression and/or complication in the subject.
- “Ameliorating” or “alleviating” a condition or state as used herein shall mean to relieve or lessen the symptoms of that condition or state.
- to “treat” or “treating” as used herein refers to the periodic administration of a substance, i.e., laquinimod, for a period of at least one month and specifically excludes periodic administration of less than one month.
- Treating as applied to patients presenting CIS can mean delaying the onset of clinically definite multiple sclerosis (CDMS) , delaying the progression to CDMS, reducing the risk of conversion to CDMS, or reducing the frequency of relapse in a patient who experienced a first clinical episode consistent with multiple sclerosis and who has a high risk of developing CDMS.
- CDMS clinically definite multiple sclerosis
- afflicted as in a patient afflicted with a disease or a condition, means a patient who has been affirmatively diagnosed to have the disease or condition.
- a patient afflicted with multiple sclerosis means a patient who has been affirmatively diagnosed to have multiple sclerosis.
- the diagnosis of the disease or condition can be effected using any of the appropriate methods known in the art. For multiple sclerosis, the diagnosis is as defined by the Revised McDonald criteria (Polman, 2011) .
- the method includes the step of determining whether a patient is a multiple sclerosis patient.
- a "patient at risk of developing MS” is a patient presenting any of the known risk factors for MS.
- the known risk factors for MS include any one of a clinically isolated syndrome (CIS) , a single attack suggestive of MS without a lesion, the presence of a lesion (in any of the CNS, PNS, or myelin sheath) without a clinical attack, environmental factors (geographical location, climate, diet, toxins, sunlight), genetics (variation of genes encoding HLA-DRB1, IL7R-alpha and IL2R-alpha) , and immunological components (viral infection such as by Epstein-Barr virus, high avidity CD4 + T cells, CD8 + T cells, anti-NF-L, anti-CSF 114 (Glc) ) .
- CIS Certenically isolated syndrome
- first clinical event and “first demyelinating event” suggestive of MS, which, for example, presents as an episode of optic neuritis, blurring of vision, diplopia, involuntary rapid eye movement, blindness, loss of balance, tremors, ataxia, vertigo, clumsiness of a limb, lack of co-ordination, weakness of one or more extremity, altered muscle tone, muscle stiffness, spasms, tingling, paraesthesia, burning sensations, muscle pains, facial pain, trigeminal neuralgia, stabbing sharp pains, burning tingling pain, slowing of speech, slurring of words, changes in rhythm of speech, dysphagia, fatigue, bladder problems (including urgency, frequency, incomplete emptying and incontinence) , bowel problems (including constipation and loss of bowel control) , impotence, diminished sexual arousal, loss of
- Confirmed Relapse is defined as the appearance of one or more new neurological abnormalities or the reappearance or worsening of one or more previously observed neurological abnormalities wherein the change in clinical state lasts at least 48 hours and is immediately preceded by an improving neurological state of at least thirty (30) days from onset of previous relapse. This criterion is different from the clinical definition of relapse which requires only 24 hours duration of symptoms. (EMEA Guideline, 2006) Since "in study" relapse definition must be supported by an objective neurological evaluation as discussed below, a neurological deficit must sustain long enough to eliminate pseudo-relapses.
- An event is a relapse only when the subject's symptoms are accompanied by observed objective neurological changes, consistent with at least one of the following: an increase of at least 0.5 in the EDSS score as compared to the previous evaluation, an increase of one grade in the score of 2 or more of the 7 FS functions as compared to the previous evaluation, or an increase of 2 grades in the score of one FS as compared to the previous evaluation.
- the subject must not be undergoing any acute metabolic changes such as fever or other medical abnormality.
- a change in bowel/bladder function or in cognitive function must not be entirely responsible for the changes in EDSS or FS scores.
- Relapse Rate is the number of confirmed relapses per unit time.
- Annualized relapse rate is the mean value of the number of confirmed relapses of each patient multiplied by 365 and divided by the number of days that patient is on the study drug.
- “Expanded Disability Status Scale” or “EDSS” is a rating system that is frequently used for classifying and standardizing the condition of people with multiple sclerosis. The score ranges from 0.0 representing a normal neurological exam to 10.0 representing death due to MS. The score is based upon neurological testing and examination of functional systems (FS) , which are areas of the central nervous system which control bodily functions. The functional systems are: Pyramidal (ability to walk) , Cerebellar (coordination) , Brain stem (speech and swallowing) , Sensory (touch and pain) , Bowel and bladder functions, Visual, Mental, and Other (includes any other neurological findings due to MS) . (Kurtzke JF, 1983)
- a “confirmed progression" of EDSS, or “confirmed disease progression” as measured by EDSS score is defined as an increase in EDSS of >1 point from baseline for subjects with baseline EDSS of ⁇ 5.0, or an increase in EDSS of >0.5 points from baseline for subjects with baseline EDSS of 5.5. In order to be considered a confirmed progression, the increase must be sustained for at least 3 months. In addition, confirmation of progression cannot be made during a relapse .
- Adverse event or "AE” means any untoward medical occurrence in a clinical trial subject administered a medicinal product and which does not have a causal relationship with the treatment.
- An adverse event can therefore be any unfavorable and unintended sign including an abnormal laboratory finding, symptom, or diseases temporally associated with the use of an investigational medicinal product, whether or not considered related to the investigational medicinal product.
- Ambulation Index or "AI” is a rating scale developed by Hauser et al . to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. Scores range from 0 (asymptomatic and fully active) to 10 (bedridden) . The patient is asked to walk a marked 25-foot course as quickly and safely as possible. The examiner records the time and type of assistance (e.g., cane, walker, crutches) needed. (Hauser, 1983)
- EQ-5D is a standardized questionnaire instrument for use as a measure of health outcome applicable to a range of health conditions and treatments. It provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as population health surveys.
- EQ-5D was developed by the "EuroQoL” Group which comprises a network of international, multilingual, multidisciplinary researchers, originally from seven centers in England, Finland, the Netherlands, Norway and Sweden. The EQ-5D questionnaire is in the public domain and can be obtained from EuroQoL.
- Gd-enhancing lesion refers to lesions that result from a breakdown of the blood-brain barrier, which appear in contrast studies using gandolinium contrast agents. Gandolinium enhancement provides information as to the age of a lesion, as Gd-enhancing lesions typically occur within a six week period of lesion formation.
- "Symbol Digit Modalities Test” or "SDMT” is a measure of cognitive function using a five minute assessment that quickly screens for cerebral dysfunction by means of a simple substitution task. The SDMT is described in, e.g., Smith, 1982; Christodoulou, 2003; Benedict, 2004; Benedict 2005; Benedict 2006; Houtchens, 2007; Benedict 2007; Warlop 2009; and Toledo, 2008.
- Magneticization Transfer Imaging or “MTI” is based on the magnetization interaction (through dipolar and/or chemical exchange) between bulk water protons and macromolecular protons. By applying an off resonance radio frequency pulse to the macromolecular protons, the saturation of these protons is then transferred to the bulk water protons. The result is a decrease in signal (the net magnetization of visible protons is reduced) , depending on the magnitude of MT between tissue macromolecules and bulk water.
- MT or “Magnetization Transfer” refers to the transfer of longitudinal magnetization from the hydrogen nuclei of water that have restricted motion to the hydrogen nuclei of water that moves with many degrees of freedom. With MTI, the presence or absence of macromolecules (e.g. in membranes or brain tissue) can be seen. (Mehta, 1996; Grossman, 1994)
- Magnetic resonance Resonance Spectroscopy is a specialized technique associated with magnetic resonance imaging (MRI) .
- MRS Magnetic resonance imaging
- the MR signal produces a spectrum of resonances that correspond to different molecular arrangements of the isotope being “excited” .
- This signature is used to diagnose certain metabolic disorders, especially those affecting the brain, (Rosen, 2007) as well as to provide information on tumor metabolism. (Golder, 2007)
- MFIS Modified Fatigue Impact Scale
- MS Functional Composite or “MSFC” is a clinical outcome measure for MS.
- the MSFC comprises quantitative functional measures of three key clinical dimensions of MS: leg function/ambulation, arm/hand function, and cognitive function. Scores on component measures are converted to standard scores (z-scores) , which are averaged to form a single MSFC score. (Fischer, 1999)
- SF-36 is a multi-purpose, short-form health survey with 36 questions which yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group.
- the survey is developed by and can be obtained from QualityMetric, Inc. of Buffalo, RI .
- T2-weighted MRI image refers to an MR-image that emphasizes T2 contrast by which lesions may be visualized. T2 lesions represent new inflammatory activity.
- a “pharmaceutically acceptable carrier” refers to a carrier or excipient that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. It can be a pharmaceutically acceptable solvent, suspending agent or vehicle, for delivering the instant compounds to the subject.
- ALLEGRO and BRAVO are two clinical trials reported in, e.g., PCT International Application Publication No. WO/2010/147665 (Tarcic et al . ) .
- ALLEGRO was a study performed in subjects with RRMS to assess the efficacy, safety and tolerability of laquinimod 0.6 mg over placebo in a double-blind design.
- the treatment duration in this study was 24 months and it enrolled 1,106 patients equally distributed between laquinimod 0.6 mg and placebo arms.
- the primary endpoint was annualized relapse rate (ARR) .
- Secondary endpoints were gadolinium-enhancing (GdE) -Tl and new-T2 lesions, time to Expanded Disability Status Scale (EDSS) progression confirmed at 3 months and multiple sclerosis functional composite (MSFC) z-score.
- GdE gadolinium-enhancing
- EDSS Expanded Disability Status Scale
- MSFC multiple sclerosis functional composite
- BRAVO was a study performed in subjects with RRMS to assess the efficacy, safety and tolerability of laquinimod 0.6 mg over placebo in a double-blind design with a reference arm of IFN-p-la (Avonex®) in a rater-blinded assessment.
- the study had treatment duration of 24 months and enrolled 1,331 subjects equally distributed between the three (3) treatment arms.
- the primary endpoint was ARR. Secondary endpoints were Brain atrophy, time to EDSS progression confirmed at 3 months and MSFC z-score.
- One of the basic assumptions used to assess the sample size for the study was that treatment with laquinimod will reduce the patient population ARR by 25% or more when compared to the placebo group. Thus, the BRAVO study was not powered to detect a statistically significant reduction of 17.7%.
- Double-blind Placebo-controlled (DBPC) period (Period 1) : At least 15 months, but not more than 24 months of once-daily, oral administration of either laquinimod 0.6 mg, 1.2 mg or matching oral placebo. DBPC period for all subjects is declared closed when all ongoing enrolled subjects complete at least 15 months of treatment.
- Active-treatment (AT) period (Period 2) : In this period (24 months), subjects who are assigned to either 0.6 mg or 1.2 mg daily oral laquinimod during the DBPC period continue with the same treatment assignment, whereas those who are assigned to placebo receive 1.2 mg daily oral laquinimod. Study Population
- Eligible subjects (approximately 1,800) are randomized in a 1:1:1 ratio into one of the following treatment arms: 1.
- Laquinimod 0.6 mg two capsules, one containing 0.6 mg laquinimod and the other containing matching placebo, administered orally once daily.
- Laquinimod 1.2 mg two capsules containing 0.6 mg laquinimod administered orally once daily.
- Matching placebo two capsules containing placebo (matching to the 0.6 mg) administered orally once daily.
- the study comprises of two treatment periods, Double-blind Placebo-controlled (DBPC) and Active-treatment (AT) . Subjects who complete 24 months on study drug in Period 1 or complete at least 15 months on study drug when Period 1 is declared closed continue on to Period 2.
- DBPC Double-blind Placebo-controlled
- AT Active-treatment
- Period 1 subjects are evaluated at study sites at months: -1 (screening), 0 (baseline), 1, 2, 3 and every 3 months thereafter until completion visit of Period 1.
- Period 1 is declared closed, subjects who complete at least
- ETD Early Treatment Discontinuation
- Period 1 serves as the baseline visit of Period 2.
- Period 2 subjects are evaluated at study sites at months OAT (baseline, completion visit of Period 1), 1AT, 2AT, 3AT and every 3 months thereafter until completion/ETD of Period 2.
- Subjects who are ETD during period 2 are followed only if indicated for resolution of AE or relapse.
- Period 1 1AT, 3AT, 6AT and every 6 months thereafter, until completion/ETD of Period 2.
- the following safety clinical laboratory tests are performed :
- CBC Complete blood count
- Serum chemistry including electrolytes, liver enzymes, urea, creatinine, calculated Glomerular Filtration Rate (GFR) - at screening and prior to each MRI scan, glucose, total protein, albumin, direct and total bilirubin and pancreatic amylase) - at all scheduled visits during the DBPC and AT periods.
- GFR Glomerular Filtration Rate
- ECG is performed at months -1 (screening) , 0 (baseline, three recordings 10 min apart, before first dose), 1, 2, 3, 6, and every 6 months thereafter until completion visit of Period 1 and ETD visit (if applicable) .
- ECG is performed at months OAT (baseline, completion visit of Period 1), 1AT, 2AT, 3AT, 6AT and every 6 months thereafter until completion/ETD of Period 2.
- MRI is performed at months OAT (baseline, completion visit of Period 1) and completion/ETD of Period 2.
- OAT baseline, completion visit of Period 1
- Neurological evaluations including Expanded Disability Status Scale (EDSS) , Functional Systems (FS) and Timed 25- foot walk (T25FW) are performed at months -1 (screening (excluding T25FW) ) , 0 (baseline) and every 3 months thereafter, ETD visit (if applicable) and until completion visit of Period 1.
- neurological evaluations including EDSS, FS and T25FW are performed at months OAT (baseline, completion visit of Period 1) and every 3 months thereafter until completion/ETD of Period 2.
- EQ-5D The general health status is assessed by the EuroQoL (EQ-5D) questionnaire at months 0 (baseline) , ETD visit (if applicable) and completion visit of Period 1. During Period 2, EQ-5D is performed at months OAT (baseline; completion visit of Period 1) and completion/ETD of Period 2.
- SF-36 Short-Form general health survey
- OAT baseline; completion visit of Period 1
- OAT baseline; completion visit of Period 2
- PGx Pharmacogenetic
- Magnetization Transfer (MT) (in selected countries and sites) is assessed at months 0 (baseline) and 15. An additional MRI is performed at completion visit of Period 1 and ETD visit (if applicable) , provided no MRI was performed within the previous 3 months .
- Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria (Polman, 2011) with relapse onset disease or a relapsing-remitting disease course .
- Subjects must be ambulatory with Kurtzke EDSS score of 0-5.5 in both screening and randomization visits.
- Subjects must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment
- NMO Neuromyelitis Optica
- immunosuppressive agents including fingolimod (Gilenya®) or cytotoxic agents, including Cyclophosphamide within 6 months prior to randomization.
- natalizumab (Tysabri®) , rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab.
- Serum levels ⁇ 3xULN of either ALT or AST at screening Serum levels ⁇ 3xULN of either ALT or AST at screening.
- Serum direct bilirubin which is ⁇ 2xULN at screening.
- Such conditions may include:
- a Central Nervous System (CNS) disorder other than MS that may jeopardize the subject's participation in the study, including such disorders that are demonstrated on the baseline MRI .
- CDP Time to Confirmed Disease Progression
- Brain atrophy as defined by the percent change in brain volume from baseline to month 15 (for subjects that performed ETD, the MRI from the ETD visit is included in the analysis provided the subject completed 9 months or treatment) .
- Exploratory endpoints include Cognitive (SDMT) , MRI and quality of life. MRI endpoints are analyzed based on scans performed at month 15 and 24. Exploratory endpoints include: ⁇ Change from baseline in the Symbol Digit Modalities Test
- Brain atrophy as defined by the percent change in brain volume from baseline to month 24. ⁇ Number of GdE-Tl lesions.
- T25FW 25-foot walk
- the primary endpoint of the study is the time to CDP during Period 1.
- the primary analysis for the comparisons between each dose of laquinimod (0.6 mg and 1.2 mg) vs. placebo is conducted utilizing the baseline adjusted Cox's proportional hazards (PH) model (SAS® PROC PHREG) .
- PH Cox's proportional hazards
- Categorical EDSS at baseline ( ⁇ 4 or >4), Country/Geographical Region (CGR) , categorical age at baseline ( ⁇ 40 or >40) and T2 volume at baseline are included as covariates in the model.
- the time to confirmed progression of EDSS is presented by Kaplan-Meier curves stratified by treatment group.
- the adequacy of the proportional hazards assumption is confirmed by including two time dependent covariates of dose by log (time) interactions in the primary analysis model and testing each of them in 5% level.
- the log rank test SAS® PROC LIFTEST is used for statistical inference in this dose.
- the analysis of the time to confirmed relapse during Period 1 is based on two contrasts between laquinimod 0.6 mg and 1.2 mg vs. placebo utilizing the baseline adjusted Cox's proportional hazards model Regression (SAS®PROC PHREG) .
- baseline EDSS score, log of the prior 2-year relapses (+1), CGR, Indicator of GdE lesions at baseline ( ⁇ 1 vs. 0) and T2 volume are used as covariates.
- the adequacy of the proportional hazards assumption is confirmed by including two time-dependent covariates of dose by log (time) interactions in the primary analysis model and testing each of them in 5% level.
- 1.2 mg/day laquinimod treatment show improved efficacy in treating RRMS patients with respect to all endpoints .
- 1.2 mg/day laquinimod treatment is more effective in shortening the time to CDP and time to confirmed relapse, reducing brain atrophy, as measured by percent brain volume change from baseline, reducing relapse rate, slowing the progression of disability, and reducing the development of new MRI lesions in RRMS patients.
- RRMS patients treated daily oral administration of 0.6 mg laquinimod or placebo experience a prolonged time to CDP.
- RRMS patients treated daily oral administration of 0.6 mg laquinimod or placebo RRMS patients treated with daily oral administration of 1.2 mg laquinimod have reduced brain atrophy, as measured by percent brain volume change from baseline to month 15.
- patients treated with daily oral administration of 1.2 mg laquinimod experience a prolonged time to first confirmed relapse.
- RRMS patients treated daily oral administration of 0.6 mg laquinimod or placebo RRMS patients treated with daily oral administration of 1.2 mg laquinimod have reduced number of confirmed relapses, which is directly related to the relapse rate.
- RRMS patients treated with daily oral administration of 1.2 mg laquinimod have improved Symbol Digit Modalities Test (SDMT) score, lower annualized relapse relate, reduced brain atrophy as measured by the percent change in brain volume from baseline to month 24, reduced the accumulation of disability as measured by the MSFC score or Timed 25-foot walk (T25FW) , reduced MRI-monitored disease activity in RRMS patients, as measured by the cumulative number of enhancing lesions on Tx-weighted images, the cumulative number of new hypointense lesions on Tuscans, the cumulative number of new T 2 lesions, number of GdE-Tl lesions, number of new T2 lesions, number of new Tl hypointense lesions (black holes) , change from baseline in T21esions volume, change from baseline in GdE-Tl lesions volume, and change or change from baseline in Tl hypointense lesions volume (black holes)
- SDMT Symbol Digit Modalities Test
- daily oral administration of 1.2 mg laquinimod is more effective in providing neuroprotection to the patients as compared to daily oral administration of 0.6 mg laquinimod or placebo .
- Rudick et al . (1999) "Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Sclerosis Collaborative Research Group”. Neurology . 53 : 1698-1704.
- Rudick, R. (1999) "Disease-Modifying Drugs for Relapsing- Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics", Neurotherpatueics . 56 : 1079-1084.
- Wegner et al "Laquinimod reduces cuprizone-induced demyelination by down modulation of astrocytic NFkB activation". Acta Neuorpathologica, submitted.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201406594UA SG11201406594UA (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
EA201492010A EA201492010A1 (en) | 2012-05-02 | 2013-05-01 | APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS |
MX2014013039A MX2014013039A (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis. |
CN201380022530.XA CN104284663A (en) | 2012-05-02 | 2013-05-01 | Use of high dose LAQUINIMOD for treating multiple sclerosis |
JP2015510436A JP2015515985A (en) | 2012-05-02 | 2013-05-01 | Use of high-dose laquinimod to treat multiple sclerosis |
KR1020147033707A KR20150013658A (en) | 2012-05-02 | 2013-05-01 | Use of High Dose Laquinimod for Treating Multiple Sclerosis |
AU2013256352A AU2013256352A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
EP13784231.6A EP2844255A4 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
BR112014027010A BR112014027010A2 (en) | 2012-05-02 | 2013-05-01 | use of high dose laquinimod for treatment of multiple sclerosis |
CA2870684A CA2870684A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
IL235337A IL235337A0 (en) | 2012-05-02 | 2014-10-26 | Use of high dose laquinimod for treating multiple sclerosis |
PH12014502447A PH12014502447A1 (en) | 2012-05-02 | 2014-10-31 | Use of high dose laquinimod for treating multiple sclerosis |
ZA2014/08820A ZA201408820B (en) | 2012-05-02 | 2014-12-02 | Use of high dose laquinimod for treating multiple sclerosis |
HK15106789.5A HK1206246A1 (en) | 2012-05-02 | 2015-07-16 | Use of high dose laquinimod for treating multiple sclerosis (laquinimod) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261641389P | 2012-05-02 | 2012-05-02 | |
US61/641,389 | 2012-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013166166A1 true WO2013166166A1 (en) | 2013-11-07 |
Family
ID=49514859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Country Status (21)
Country | Link |
---|---|
US (3) | US20130303569A1 (en) |
EP (1) | EP2844255A4 (en) |
JP (2) | JP2015515985A (en) |
KR (1) | KR20150013658A (en) |
CN (2) | CN104284663A (en) |
AR (1) | AR090885A1 (en) |
AU (1) | AU2013256352A1 (en) |
BR (1) | BR112014027010A2 (en) |
CA (1) | CA2870684A1 (en) |
CL (1) | CL2014002935A1 (en) |
EA (1) | EA201492010A1 (en) |
HK (1) | HK1206246A1 (en) |
IL (1) | IL235337A0 (en) |
MX (1) | MX2014013039A (en) |
PE (1) | PE20150161A1 (en) |
PH (1) | PH12014502447A1 (en) |
SG (1) | SG11201406594UA (en) |
TW (2) | TW201804997A (en) |
UY (1) | UY34775A (en) |
WO (1) | WO2013166166A1 (en) |
ZA (1) | ZA201408820B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2830623A4 (en) * | 2012-03-27 | 2015-09-02 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014008731A2 (en) | 2011-10-12 | 2017-04-25 | Teva Pharma | multiple sclerosis treatment with combination of laquinimode and fingolimode |
JP2015505564A (en) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | Use of laquinimod to treat patients with Crohn's disease who have failed first-line anti-TNEα therapy |
KR20140138725A (en) | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
BR112015007782A2 (en) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod to reduce thalamic damage in multiple sclerosis |
MX2015005632A (en) | 2012-11-07 | 2016-02-05 | Teva Pharma | Amine salts of laquinimod. |
AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
AR098924A1 (en) * | 2013-12-23 | 2016-06-22 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND TERIFLUNOMIDE |
EP3137092A4 (en) * | 2014-04-29 | 2017-10-11 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
UA127744C2 (en) * | 2018-07-20 | 2023-12-20 | Мерк Патент Гмбх | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
BR112014008731A2 (en) * | 2011-10-12 | 2017-04-25 | Teva Pharma | multiple sclerosis treatment with combination of laquinimode and fingolimode |
AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
-
2013
- 2013-04-29 AR ARP130101459A patent/AR090885A1/en unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/en unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/en unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/en not_active Application Discontinuation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/en unknown
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/en active Pending
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/en not_active Application Discontinuation
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/en not_active Application Discontinuation
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/en not_active Withdrawn
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/en active Pending
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/en unknown
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en active Application Filing
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/en not_active IP Right Cessation
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/en unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-07-16 HK HK15106789.5A patent/HK1206246A1/en unknown
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7560100B2 (en) * | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
Non-Patent Citations (3)
Title |
---|
POLMAN ET AL.: "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.", NEUROLOGY, vol. 64, 2005, pages 987 - 991, XP055172276, Retrieved from the Internet <URL:http://www.direct-ms.org/sites/defaulUfiles/Laquinimod%20MRI%20Lesions.pdf> [retrieved on 20130912] * |
PREININGEROVA, J.: "Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin. Investig.", DRUGS., vol. 18, no. 7, 2009, pages 985 - 989, XP008157941, Retrieved from the Internet <URL:http://ccs01.vo.ca-cncx.net/o41/5507/bw/bs/FPCR20100005/articles/L614MS1.pdf> [retrieved on 20130912] * |
See also references of EP2844255A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2830623A4 (en) * | 2012-03-27 | 2015-09-02 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Also Published As
Publication number | Publication date |
---|---|
ZA201408820B (en) | 2016-06-29 |
TW201347762A (en) | 2013-12-01 |
EP2844255A4 (en) | 2015-10-14 |
PH12014502447A1 (en) | 2015-01-12 |
KR20150013658A (en) | 2015-02-05 |
CA2870684A1 (en) | 2013-11-07 |
BR112014027010A2 (en) | 2017-06-27 |
EA201492010A1 (en) | 2015-06-30 |
US20130303569A1 (en) | 2013-11-14 |
AU2013256352A1 (en) | 2014-11-27 |
CL2014002935A1 (en) | 2015-03-06 |
PE20150161A1 (en) | 2015-02-22 |
MX2014013039A (en) | 2015-02-04 |
JP2017222691A (en) | 2017-12-21 |
CN105832733A (en) | 2016-08-10 |
JP2015515985A (en) | 2015-06-04 |
TW201804997A (en) | 2018-02-16 |
US20160000775A1 (en) | 2016-01-07 |
IL235337A0 (en) | 2014-12-31 |
SG11201406594UA (en) | 2014-11-27 |
AR090885A1 (en) | 2014-12-10 |
EP2844255A1 (en) | 2015-03-11 |
HK1206246A1 (en) | 2016-01-08 |
UY34775A (en) | 2013-11-29 |
US20150265592A1 (en) | 2015-09-24 |
CN104284663A (en) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160000775A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
DK2442651T3 (en) | Treatment of multiple sclerosis with laquinimod | |
US20120142730A1 (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
US20180064702A1 (en) | Treatment of progressive forms of multiple sclerosis with laquinimod | |
AU2013329348A1 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
US20170151224A1 (en) | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13784231 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2870684 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015510436 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001911-2014 Country of ref document: PE Ref document number: MX/A/2014/013039 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014002935 Country of ref document: CL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013784231 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013256352 Country of ref document: AU Date of ref document: 20130501 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201407517 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 20147033707 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201492010 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014027010 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014027010 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141029 |